Back

BMPR-II biomarkers for testing therapeutic efficacy in pulmonary arterial hypertension: The StratosPHere 1 study.

2025-12-20 respiratory medicine Title + abstract only
View on medRxiv
Show abstract

Pulmonary arterial hypertension (PAH) is a rare, life-limiting disease where deficiency of the TGF/BMP pathways have causal roles in hereditary and idiopathic forms. It is an attractive candidate for therapeutic intervention but there is an unmet need for clinically-relevant and practical biomarkers that can measure target engagement. A major challenge has been the inaccessibility of lung tissue in disease for molecular profiling. Here we explore the surrogate capacity of peripheral blood BMP pa...

Predicted journal destinations